Vericel (VCEL) Insider Jonathan Siegal Buys $75K of Stock

Jonathan Siegal, the Principal Accounting Officer at Vericel Corporation, recently bought 2,500 shares of the company. This purchase, made on June 26, 2026, was valued at $74,550, with each share priced at $29.82. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Vericel Corporation

On June 26, 2026, several insider transactions took place at Vericel Corporation. Jonathan Siegal, the Principal Accounting Officer, bought 2,500 shares at $29.82 each. On the same day, he also sold 2,732 shares at $44.90 under a planned transaction. Jonathan Hopper, the Chief Medical Officer, acquired 5,000 shares at $29.82. Additionally, Sean Flynn, the Chief Legal Officer, purchased 15,000 shares at $16.25 and sold 15,000 shares at $45.64 under a planned sale.

Other Institutional Activity in Vericel Corporation

Several institutional investors adjusted their positions in Vericel Corporation. BlackRock, Inc. increased its holdings by 58,269 shares, ending with 7,765,344 shares valued at approximately $249.8 million. Soleus Capital Management, L.P. made a significant move by adding 1,785,079 shares, growing its stake by 233.6% to 2,549,079 shares worth about $82 million. Conestoga Capital Advisors, LLC increased its position by 208,750 shares, achieving a 9.3% increase to 2,463,312 shares valued at approximately $79.2 million. Meanwhile, State Street Corp reduced its holdings by 11,792 shares, with its total now at 3,152,130 shares, valued at $101.4 million.

Vericel Corporation Stock Up 11.2%

Shares of NasdaqGM:VCEL traded near $44.49 on Wednesday. Vericel Corporation, a player in the healthcare sector, has a market cap of about $2.27 billion. The stock's price-to-earnings (P/E) ratio stands at 103.47, with a forward P/E of 52.22, indicating high growth expectations. The company's beta is 1.132, suggesting slightly higher volatility compared to the market. Over the past 52 weeks, the stock has ranged from $28.95 to $46.62. The 50-day moving average is $36.28, and the 200-day moving average is $35.73. The company maintains a strong current ratio of 5.18 and a quick ratio of 4.62, with a debt-to-equity ratio of 26.68.

Analysts Set New Price Targets

Analyst sentiment remains positive for Vericel Corporation. On April 15, 2026, Truist Securities maintained its buy rating with a price target of $42.00. Earlier, on February 27, 2026, HC Wainwright & Co. also maintained a buy rating, setting a target of $64.00. The consensus among analysts is a buy rating, with an average price target of $55.43 based on seven opinions.

About Vericel Corporation

Vericel Corporation is a biopharmaceutical company based in Burlington, Massachusetts. It focuses on developing and manufacturing cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company's key products include MACI, Epicel, and NexoBrid, which are used in cartilage repair and burn treatment. Vericel was originally known as Aastrom Biosciences, Inc. before changing its name in 2014. The company was incorporated in 1989 and employs around 398 people under the leadership of CEO Dominick C. Colangelo.

Bottom Line

Jonathan Siegal's recent purchase of Vericel shares highlights insider confidence in the company's prospects. Investors often track insider transactions for potential insights into a company's future performance. It's important to remember that these transactions are reported after they occur and may not reflect current insider sentiment. Vericel Corporation's stock performance and analyst ratings suggest ongoing interest in its growth potential.